SVRA — Savara Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1160308 ·
Last close
$6.03
Market Cap
$1.24B
52W High
$6.47
52W Low
$4.70
ADV30
2,034,051
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -38,137,000 | -37,284,000 | 221,645,000 | 38,791,000 | 45,606,000 |
| Dec 2025 | 0 | — | -33,419,000 | -32,236,000 | 253,436,000 | 33,180,000 | 50,303,000 |
| Sep 2025 | 0 | — | -30,255,000 | -29,561,000 | 140,924,000 | 16,277,000 | 46,538,000 |
| Jun 2025 | 0 | — | -31,440,000 | -30,401,000 | 163,765,000 | 17,436,000 | 43,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-106,894,000
Investing CF
$-8,991,000
Financing CF
$135,293,000
CapEx
$-73,000
Dividends Paid
—
Buybacks
$-5,165,000
EPS Diluted TTM
$-0.55
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-645,371,000
Inventory
—
Receivables
$1,053,000
ST Investments
$163,981,000
EBIT TTM
$-133,251,000
Pretax Income TTM
$-129,482,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,763,000 | -118,837,000 | 253,436,000 | 50,303,000 | — | -101,037,000 |
| Dec 2024 | 0 | -102,399,000 | -95,881,000 | 212,879,000 | 41,430,000 | — | -89,088,000 |
| Dec 2023 | 0 | -59,210,000 | -54,698,000 | 177,564,000 | 37,192,000 | — | -51,061,000 |
| Dec 2022 | 0 | -38,043,000 | -38,150,000 | 139,777,000 | 31,999,000 | — | -34,554,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.24B | $28.06 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $1.25B | $21.51 | — |
| MNKD | MANNKIND CORP | $1.26B | $4.09 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.26B | $36.24 | — |
| WVE | Wave Life Sciences Ltd. | $1.20B | $6.25 | — |
News headlines (Yahoo Finance, 1h cache)
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
2026-06-30 11:30 · Yahoo
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
2026-06-27 15:34 · Yahoo
Savara Announces New Employment Inducement Grant
2026-06-12 20:05 · Yahoo
Savara Announces Chief Financial and Administrative Officer Transition
2026-06-08 20:05 · Yahoo
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
2026-06-08 17:13 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
Savara Inc. (SVRA) Reports Q1 Financial Results
2026-05-22 18:43 · Yahoo
US High Growth Tech Stocks To Watch
2026-04-27 17:38 · Yahoo
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
2026-04-26 17:03 · Yahoo
High Growth Tech Stocks To Watch In The US March 2026
2026-03-26 11:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.